News
CMXHF
115.20
NaN%
--
CSL Limited Releases Update on Share Buy-Back Program
TipRanks · 12/17/2025 22:19
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and CSL (OtherCMXHF)
TipRanks · 12/16/2025 23:10
Ord Minnett Remains a Hold on CSL (CMXHF)
TipRanks · 12/16/2025 00:35
CSL Limited Updates on Share Buy-Back Progress
TipRanks · 12/14/2025 21:58
CSL Limited Updates on Ongoing Share Buy-Back Program
TipRanks · 12/10/2025 21:45
CSL Limited Updates on Daily Buy-Back Progress
TipRanks · 12/07/2025 22:47
CSL Reports Five-Year Data Confirming Long-Term Safety and Efficacy of HEMGENIX for Hemophilia B
Reuters · 12/07/2025 17:01
CSL Limited Announces Cessation of Securities
TipRanks · 12/05/2025 01:07
CSL Limited Updates on Share Buy-Back Progress
TipRanks · 12/04/2025 21:57
Morgan Stanley Sticks to Their Buy Rating for CSL (CMXHF)
TipRanks · 12/03/2025 23:07
BUZZ-Morningstar sees Australia's CSL as 'cheap', optimistic for margin rebound
Reuters · 12/03/2025 19:06
CSL Limited Appoints Gordon Naylor as Director
TipRanks · 12/03/2025 02:57
CSL Limited Announces Issuance of Unquoted Equity Securities
TipRanks · 12/03/2025 02:47
CSL Limited Updates on Share Buy-Back Program
TipRanks · 11/26/2025 22:08
CSL Limited Updates on Ongoing Share Buy-Back
TipRanks · 11/25/2025 22:29
Jarden Sticks to Its Buy Rating for CSL (CMXHF)
TipRanks · 11/25/2025 00:36
CSL Limited Director Increases Stake with Significant ADR Purchase
TipRanks · 11/23/2025 21:57
CSL Limited Updates on Market Buy-Back Program
TipRanks · 11/23/2025 21:57
Washington state resident dies from bird flu strain never before detected in humans
Seeking Alpha · 11/22/2025 13:33
CSL Limited Updates on Ongoing Share Buy-Back Program
TipRanks · 11/20/2025 21:43
More
Webull provides a variety of real-time CMXHF stock news. You can receive the latest news about CSL through multiple platforms. This information may help you make smarter investment decisions.
About CMXHF
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.